AUS
NZ
UK
CA
USA
IND
_07_03_2026_03_50_21_133108.jpg)
On July 25, 2026, Kathryn Michelle Armstrong, Chief Scientific Officer of USANA Health Sciences Inc., completed a transaction involving the acquisition of common stock through restricted stock unit vesting, as disclosed in a filing dated July 27, 2026. Armstrong acquired 1,166 shares via restricted stock unit vesting while simultaneously disposing of 518 shares through a cashless exercise. After these transactions, Armstrong's direct beneficial ownership in the nutrition and wellness company totaled 3,989 shares of common stock.
Key Points
- USANA Health Sciences trades on NYSE under the ticker USNA
- Chief Scientific Officer Kathryn Michelle Armstrong acquired 1,166 shares through restricted stock unit vesting on July 25, 2026
- Armstrong sold 518 shares at $21.32 per share in the same transaction, resulting in a net direct ownership of 3,989 common shares
- Post-transaction, Armstrong holds 39,426 restricted stock units that vest 25% annually starting July 25, 2024
Details of the Equity Transaction Executed by Armstrong
The Form 4 filing submitted on July 27, 2026, reveals a multi-faceted equity transaction by USANA’s Chief Scientific Officer. On July 25, 2026, Armstrong participated in a routine equity compensation event involving the vesting of 1,166 restricted stock units (RSUs), classified under transaction code "M," which typically denotes equity compensation such as RSU vesting. Concurrently, she disposed of 518 shares at $21.32 each under transaction code "F," commonly associated with open market or cashless exercise transactions.
The simultaneous acquisition and disposition on the same date indicate Armstrong likely executed a cashless exercise or net-share settlement arrangement. This approach allows executives to fulfill tax withholding or exercise costs by selling a portion of vested shares immediately, maintaining their overall equity stake without out-of-pocket expenses.
Impact on Armstrong's Beneficial Ownership
Following these transactions, Armstrong’s direct beneficial ownership of USANA common stock stands at 3,989 shares. This net figure results from acquiring 1,166 shares through RSU vesting and disposing of 518 shares during the same trading session. These figures reflect only direct ownership and exclude any indirect holdings through trusts or other entities not reported in this filing. The immediate effect on USANA’s stock price was not publicly disclosed.
Additionally, Armstrong’s RSU holdings increased to 39,426 units post-transaction. These RSUs vest at a rate of 25% annually starting July 25, 2024, indicating a four-year vesting schedule commencing from the grant date in July 2024.
Restricted Stock Unit Vesting Schedule and Future Equity Accrual
The disclosed RSU vesting schedule grants Armstrong the right to receive one share of USANA common stock per unit upon vesting. With 39,426 units outstanding and a 25% annual vesting rate beginning July 25, 2024, Armstrong is expected to vest approximately 9,857 shares each year, assuming no changes to the schedule. This vesting structure aligns with typical executive compensation practices, fostering long-term shareholder value.
The filing shows no acceleration clauses, performance conditions, or contingencies affecting the vesting timeline. Approximately one-quarter of the RSUs are set to vest annually on July 25, providing transparency to both Armstrong and investors regarding future equity compensation and potential dilution.
Role and Compensation Significance of Armstrong’s Position
As Chief Scientific Officer, Armstrong holds a senior leadership role at USANA Health Sciences, overseeing research, development, and scientific affairs critical to product innovation and regulatory compliance. Equity compensation at this level reflects the company’s efforts to attract and retain key talent essential to strategic and operational success.
Insider transaction disclosures like this offer investors insight into management’s investment decisions and confidence in the company. Armstrong’s simultaneous acquisition and disposition of shares are consistent with standard tax withholding practices related to RSU vesting rather than indicative of discretionary trading intent.
Transaction Execution and Regulatory Filing Details
The filing was signed on July 27, 2026, by Joshua Foukas, attorney-in-fact for Armstrong, authorized to execute securities transactions and submit disclosures on her behalf. This arrangement is common for executives delegating administrative securities matters. The filing complies with Section 16(a) of the Securities Exchange Act of 1934, requiring timely reporting of insider transactions.
The document includes standard legal certifications warning that false statements or omissions constitute federal crimes under 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). The filing adheres to SEC regulations governing Form 4 submissions, including correct transaction codes, security identification, and clear differentiation of direct versus indirect ownership.
Compliance and Market Transparency in Insider Reporting
This disclosure exemplifies the regulatory framework ensuring market transparency of insider trading activities. Section 16 mandates officers, directors, and significant shareholders report beneficial ownership changes within two business days. USANA’s timely filing demonstrates adherence to these federal securities laws designed to protect investors and deter unlawful insider trading.
Investors should distinguish routine RSU vesting events from discretionary open market trades when interpreting insider filings. The annual vesting schedule suggests periodic equity compensation events rather than active trading decisions, aiding accurate assessment of executive sentiment.
USANA’s Executive Equity Compensation and Stock Valuation Context
The transaction highlights USANA’s structured approach to executive compensation through RSUs, aligning leadership incentives with shareholder interests over multiple years. The disclosed $21.32 per share price for the share disposition offers a market reference point for USANA’s stock valuation on July 25, 2026, reflecting the fair market value used in the cashless exercise or tax withholding sale.
Future Ownership Composition and Monitoring Considerations
Armstrong’s beneficial ownership post-transaction includes 3,989 vested common shares and 39,426 unvested RSUs. Vested shares confer full voting and economic rights, while RSUs represent contingent rights converting to shares upon vesting. The filing does not specify whether these RSUs carry dividend equivalents or voting rights, which are typically detailed in the company’s equity plan documents.
This snapshot does not forecast future ownership changes, which will evolve as RSUs vest annually. Additional equity awards or open market transactions by Armstrong would require separate insider filings. Investors tracking executive ownership should review ongoing disclosures to identify trends in equity accumulation, disposition, or tax planning that may provide insights into management’s outlook on USANA.
